EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products

Sara Carolina Henriques iD, Ana Leblanc iD, Sérgio Simões iD, Marlene Fonseca iD, Francisco Luís Pimentel iD, Luis Almeida iD, Nuno Elvas Silva iD

Pharmaceutics · 11.12.2024 · 16 (12) · 1579

DOI: 10.3390/pharmaceutics16121579 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 11.12.2024. Verfasst von Sara Carolina Henriques und 6 weiteren Autor:innen. Beteiligte Einrichtung: BlueClinical Ltd., Senhora da Hora, 4460-439 Matosinhos, Portugal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bluepharma-Indústria Farmacêutica, S.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

When companies are uncertain about the potential of a new formulation to be bioequivalent to a Reference product, it is common practice to carry out downsized pilot studies as a gatekeeping in vivo strategy to decide whether to move forward or not with a full-size pivotal study. However, due to the small study size, these studies are inarguably more sensitive to variability.

Objectives

To address and mitigate the uncertainty of the conclusions of pilot studies concerning the maximum observed concentration (Cmax), the f2 factor was proposed as an alternative approach to the average bioequivalence statistical methodology.

Methods

In this work, the alternative methodology is applied to pharmacokinetic data from pilot bioequivalence trials performed with pazopanib 200 mg and 400 mg.

Results

Despite the small sample size, and very high intra-subject variability, the f2 factor demonstrated the potential for predicting bioequivalence. The positive results were confirmed in the full sized pivotal studies.

Conclusions

In conclusion, this alternate methodology shows promise in reducing uncertainty associated with pilot studies and aiding in decisions to go forward with pivotal bioequivalence studies.

Schlagwörter

Stichwörter der Autor:innen

bioequivalencef2 factorgeneric medicinal productshighly variable drugspazopanibpharmacokineticspilot studies

Autor:innen und Institutionen

  • BlueClinical Ltd., Senhora da Hora, 4460-439 Matosinhos, Portugal.
  • Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
  • Bluepharma-Indústria Farmacêutica, S.A., São Martinho do Bispo, 3045-016 Coimbra, Portugal.
  • Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
  • Department of Biomedicine, Unit of Pharmacology & Therapeutics, Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal.
  • MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, 4200-450 Porto, Portugal.

ORCID-Profile: Sara Carolina Henriques, Ana Leblanc, Sérgio Simões, Marlene Fonseca, Francisco Luís Pimentel, Luis Almeida, Nuno Elvas Silva

Förderung

  • Bluepharma-Indústria Farmacêutica, S.A.

Zitieren

APA

Henriques, S. C., Leblanc, A., Simões, S., Fonseca, M., Pimentel, F. L., Almeida, L., & Silva, N. E. (2024). Unveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products. Pharmaceutics, 16(12), 1579. https://doi.org/10.3390/pharmaceutics16121579

Vancouver

Henriques SC, Leblanc A, Simões S, Fonseca M, Pimentel FL, Almeida L, et al. Unveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products. Pharmaceutics. 2024;16(12):1579. doi:10.3390/pharmaceutics16121579

BibTeX
@article{Henriques2024,
  author = {Henriques, Sara Carolina and Leblanc, Ana and Simões, Sérgio and Fonseca, Marlene and Pimentel, Francisco Luís and Almeida, Luis and Silva, Nuno Elvas},
  title = {Unveiling the Potential of Cmax f2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {12},
  pages = {1579},
  doi = {10.3390/pharmaceutics16121579}
}
Kostenlos starten →